Ranolazine

This classification denotes an enzyme inhibitor and cardiotonic agent with the molecular formula C24H33N3O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier A6IEZ5M406, chemically known as 1-piperazineacetamide, n-(2,6-dimethylphenyl)-4-(2-hydroxy-3-(2-methoxyphenoxy)propyl)- but generally known as ranolazine, which bears US NIH Compound Identifier 56959. European Medicines Agency schedules Ranolazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10259MIG. The term RANOLAZINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 1, No. 4, 1987, List 27). World Health Organization schedules ranolazine in its Anatomical Therapeutic Chemical (ATC) Classification. RANOLAZINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule ranolazine under HS 29335995 and SITC 51576. As of Q4 2014, RANOLAZINE remains the US FDA Preferred Term for this commodity. Ranolazine bears US NLM identifiers UMLS ID C0073633 and NCI Concept Code C66507. SMILES: OC(CN1CCN(CC1)CC(=O)NC1C(CCCC1C)C)COC1C(OC)CCCC1.